EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN

Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced patients, their management and outcome. Study Design: Cross sectional study. Place and Duration of Study: Ruth KM Pfau Civil Hospital, Karachi Pakistan, from Apr 2018 to Apr 2020. Methodology: In this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Farzana Batool, Sohaima Manzoor, Azizullah Khan Dhiloo, Humera Muhammad Ismail, Shah Muhammad Shaikh, Shehla Baqi
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	antiretroviral therapy dolutegravir efficacy hiv integrase inhibitor outcome pakistan Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c6a188763809449787da9884b5a60b12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6a188763809449787da9884b5a60b12
record_format	dspace
spelling	oai:doaj.org-article:c6a188763809449787da9884b5a60b122021-11-18T07:00:08ZEXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN0030-96482411-8842https://doaj.org/article/c6a188763809449787da9884b5a60b122021-10-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/6288/3596https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced patients, their management and outcome. Study Design: Cross sectional study. Place and Duration of Study: Ruth KM Pfau Civil Hospital, Karachi Pakistan, from Apr 2018 to Apr 2020. Methodology: In this study all treatment-naïve and experienced HIV infected patients were included and started on integrase strand-transfer inhibitor dolutegravir (DTG) containing fixed dose combination at Sindh AIDS Control Program (SACP) was conducted. We documented virological suppression, defined as a viral load of <1000 copies/ml, immunological and clinical outcomes. Results: Eighty-two patients, of whom 53 (64.6%) were ARV naïve and 29 (35.4%) experienced, were started on DTG. Fifty six (68.3%) were males. The median age was 31.6 ± 9. Of 82, 61 returned for their first follow-up visit for assessment and viral load determination. Of 61, adverse effects to DTG were reported in 12 (19.6%), including 9 with pruritis. Of 35 naive patients, 30 achieved virological suppression by 3.3 ± 0.7 months and 1 at 8 months. All 26 experienced patients achieved virological suppression by 4.5 ± 0.9 months. Overall, of 61 patients, 57 (93.4%) achieved virological suppression, of whom 1 had immunelogical failure and none had clinical failure after 6 months of DTG. Three (3.6%) patients died within the first two months of initiating DTG. Conclusion: Dolutegravir has good tolerability, with virological suppression achieved in the majority, including in highly ARV experienced patients.Farzana BatoolSohaima ManzoorAzizullah Khan DhilooHumera Muhammad IsmailShah Muhammad ShaikhShehla BaqiArmy Medical College Rawalpindiarticleantiretroviral therapydolutegravirefficacyhivintegrase inhibitoroutcomepakistanMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 5, Pp 1661-1665 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antiretroviral therapy dolutegravir efficacy hiv integrase inhibitor outcome pakistan Medicine R Medicine (General) R5-920
spellingShingle	antiretroviral therapy dolutegravir efficacy hiv integrase inhibitor outcome pakistan Medicine R Medicine (General) R5-920 Farzana Batool Sohaima Manzoor Azizullah Khan Dhiloo Humera Muhammad Ismail Shah Muhammad Shaikh Shehla Baqi EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
description	Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced patients, their management and outcome. Study Design: Cross sectional study. Place and Duration of Study: Ruth KM Pfau Civil Hospital, Karachi Pakistan, from Apr 2018 to Apr 2020. Methodology: In this study all treatment-naïve and experienced HIV infected patients were included and started on integrase strand-transfer inhibitor dolutegravir (DTG) containing fixed dose combination at Sindh AIDS Control Program (SACP) was conducted. We documented virological suppression, defined as a viral load of <1000 copies/ml, immunological and clinical outcomes. Results: Eighty-two patients, of whom 53 (64.6%) were ARV naïve and 29 (35.4%) experienced, were started on DTG. Fifty six (68.3%) were males. The median age was 31.6 ± 9. Of 82, 61 returned for their first follow-up visit for assessment and viral load determination. Of 61, adverse effects to DTG were reported in 12 (19.6%), including 9 with pruritis. Of 35 naive patients, 30 achieved virological suppression by 3.3 ± 0.7 months and 1 at 8 months. All 26 experienced patients achieved virological suppression by 4.5 ± 0.9 months. Overall, of 61 patients, 57 (93.4%) achieved virological suppression, of whom 1 had immunelogical failure and none had clinical failure after 6 months of DTG. Three (3.6%) patients died within the first two months of initiating DTG. Conclusion: Dolutegravir has good tolerability, with virological suppression achieved in the majority, including in highly ARV experienced patients.
format	article
author	Farzana Batool Sohaima Manzoor Azizullah Khan Dhiloo Humera Muhammad Ismail Shah Muhammad Shaikh Shehla Baqi
author_facet	Farzana Batool Sohaima Manzoor Azizullah Khan Dhiloo Humera Muhammad Ismail Shah Muhammad Shaikh Shehla Baqi
author_sort	Farzana Batool
title	EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
title_short	EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
title_full	EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
title_fullStr	EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
title_full_unstemmed	EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
title_sort	experience with dolutegravir in hiv patients at a public sector hospital in karachi, pakistan
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doaj.org/article/c6a188763809449787da9884b5a60b12
work_keys_str_mv	AT farzanabatool experiencewithdolutegravirinhivpatientsatapublicsectorhospitalinkarachipakistan AT sohaimamanzoor experiencewithdolutegravirinhivpatientsatapublicsectorhospitalinkarachipakistan AT azizullahkhandhiloo experiencewithdolutegravirinhivpatientsatapublicsectorhospitalinkarachipakistan AT humeramuhammadismail experiencewithdolutegravirinhivpatientsatapublicsectorhospitalinkarachipakistan AT shahmuhammadshaikh experiencewithdolutegravirinhivpatientsatapublicsectorhospitalinkarachipakistan AT shehlabaqi experiencewithdolutegravirinhivpatientsatapublicsectorhospitalinkarachipakistan
_version_	1718424069280366592

EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN

Ejemplares similares